Intervacc AB (publ) (STO:IVACC)
0.9150
+0.0530 (6.15%)
Feb 5, 2026, 5:22 PM CET
Intervacc AB Revenue
Intervacc AB had revenue of 5.38M SEK in the quarter ending September 30, 2025, with 112.49% growth. This brings the company's revenue in the last twelve months to 21.09M, up 127.13% year-over-year. In the year 2024, Intervacc AB had annual revenue of 11.79M with 46.84% growth.
Revenue (ttm)
21.09M
Revenue Growth
+127.13%
P/S Ratio
14.79
Revenue / Employee
1.41M
Employees
15
Market Cap
311.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.79M | 3.76M | 46.84% |
| Dec 31, 2023 | 8.03M | -4.33M | -35.01% |
| Dec 31, 2022 | 12.35M | 3.43M | 38.43% |
| Dec 31, 2021 | 8.92M | 1.91M | 27.20% |
| Dec 31, 2020 | 7.02M | -7.41M | -51.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Xbrane Biopharma AB | 259.70M |
| Bio-Works Technologies AB | 46.43M |
| Elicera Therapeutics AB | 13.70M |
| Corline Biomedical AB | 8.88M |
| Medivir AB | 3.88M |
| Xintela AB | 2.96M |
| Lipum AB | 398.00K |
Intervacc AB News
- 2 months ago - What To Expect From Intervacc AB (OSTO:IVACC) Q3 2025 Earnings - GuruFocus